Global biopharmaceutical company Bristol Myers Squibb (BMS) has received US Food and Drug Administration (USFDA) approval for its new CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi
Once the authorisation is issued, Johnson & Johnson plans to immediately supply the vaccine to the US government, with 100 million doses to be distributed in the country
The development programme commences immediately with an aim to introduce the vaccine in 2022, post regulatory approval. This vaccine will be developed with a potential for a multi-valent
With the distribution agreement, Ocugen will have the rights to the vaccine candidate in the US and will also be accountable for clinical development, regulatory approval and commercialisation
The Couvet site is a state-of-the-art manufacturing facility with commercial-scale capacity to produce capsule and tablet dosage forms. For WuXi STA, the Couvet site will be its first
The antibody therapies, which are administered via intravenous infusion, have secured Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for treating high-risk patients mild
The authorisation was granted after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency reviewed the primary data from the vaccine’s Phase III
The study was led by Torri Metz of University of Utah Health and Rebecca Clifton of George Washington University’s Milken Institute School of Public Health. When compared to
The study aims to identify the types of lung cells targeted by the virus and the resulting reaction due to the infection. In some of the most severe
As per the agreement, Sanofi will manufacture 125 million doses of the Covid-19 vaccine in Europe. Initial supplies of vaccine are expected to come out of Sanofi’s facilities
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.